The pre-Series A funding round for BioSapien, the innovative biotech company that created the ground-breaking localized cancer treatment platform MediChipTM, has been successfully expanded to $7 million. This milestone marks its first deployment through its dedicated MENA Fund and includes new strategic investment from top investors, including Golden Gate Ventures.
The UAE’s progressive healthcare initiatives and the pressing need to address rising cancer rates make this the perfect time for BioSapien to grow. MediChipTM offers a revolutionary method by utilizing cutting-edge 3D printing technology to deliver localized, targeted treatment, lessen systemic side effects, and enhance patient outcomes. The UAE’s emphasis on using technology to improve people’s quality of life is perfectly aligned with this innovation.
As the UAE gains recognition as a global leader in health innovation, this investment furthers BioSapien’s dedication to developing patient-centered oncology solutions. With clinical trials for BioSapien’s patented 3D-printed, slow-release drug delivery platform, MediChipTM, scheduled to start in Q2 2025, the funding will expedite these trials in the United Arab Emirates. The funds will also be used for expanding manufacturing capabilities and product development.
The mission of BioSapien is greatly aided by the UAE’s commitment to promoting innovative medical developments. Abu Dhabi’s standing as a global center for healthcare innovation has been strengthened by the first-in-region clinical trials of MediChipTM. Working with regional partners highlights the Gulf region’s potential to be a major force in developing innovative solutions to the world’s healthcare problems.
The extension comes after MENA’s top venture capital firm, Global Ventures, led a $5.5 million pre-Series A funding round in December, with Dara Holdings also participating.
Khatija Ali, CEO and Founder of BioSapien, said:
“We are delighted to announce our new investment and are grateful for all the support we have received. The expertise and belief in our vision from our investors come at a critical juncture as we initiate clinical trials in Abu Dhabi. Together, we are working towards a future where localised cancer treatment becomes the global standard.”
Michael Lints, Partner at Golden Gate Ventures MENA, commented:
“Having met CEO and Founder Khatija at Hub71 in Abu Dhabi, we were instantly impressed by her passion and vision. Investing in BioSapien aligns with our commitment to supporting transformative technologies that address significant global challenges. This investment not only supports a groundbreaking technology but also reinforces the Gulf region’s role as a global leader in healthcare innovation.”
MediChipTM, the flagship product of BioSapien, is a slow-release, 3D-printed drug delivery platform that can be attached to any tissue and has few systemic side effects.
MediChipTM reduces the negative effects of systemic chemotherapy by delivering medication straight to the tumor. Additionally, local delivery allows for the effective treatment of the tumor with smaller dosages of medication.
With the potential to expand to other cancers (such as lung and pancreatic) and non-cancer indications like opioids, hormones, biologics, and cell and gene therapies, BioSapien is first building its platform for clinical trials in patients with colorectal cancer. By 2035, the company wants to use its adaptable technology to treat over a million patients.
